Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study